SEC Form 4 · accession 0001017491-16-000097
SEELOS THERAPEUTICS, INC. · SEEL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kleanthis G Xanthopoulos
Director
Period of report
Jan 4, 2016
Accepted (ET)
Jan 5, 2016 · 1:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001017491
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $0.97 | Jan 4, 2016 | A | 50,000 | A | — | Jan 3, 2026 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The options to purchase shares of common stock were issued to the Reporting Person, a non-employee director of the Issuer, as an annual stock option grant for his service as a director of the Issuer.
- F2The options shall vest with respect to 1/12th of the underlying shares monthly, commencing with the first monthly vesting date of February 1, 2016, so that such options are fully vested on January 1, 2017.